Mersana Therapeutics Stock Fundamentals
| MRSN Stock | USD 2.88 0.33 10.28% |
Mersana Therapeutics fundamentals help investors to digest information that contributes to Mersana Therapeutics' financial success or failures. It also enables traders to predict the movement of Mersana Stock. The fundamental analysis module provides a way to measure Mersana Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mersana Therapeutics stock.
At this time, Mersana Therapeutics' Interest Income is very stable compared to the past year. As of the 25th of April 2024, Interest Expense is likely to grow to about 4.3 M, while Depreciation And Amortization is likely to drop about 1.1 M. Mersana | Select Account or Indicator |
Mersana Therapeutics Company Return On Asset Analysis
Mersana Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mersana Therapeutics Return On Asset | -0.38 |
Most of Mersana Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mersana Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Mersana Total Assets
Total Assets |
|
Based on the latest financial disclosure, Mersana Therapeutics has a Return On Asset of -0.3813. This is 95.64% lower than that of the Biotechnology sector and 98.38% lower than that of the Health Care industry. The return on asset for all United States stocks is 172.36% higher than that of the company.
Mersana Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mersana Therapeutics's current stock value. Our valuation model uses many indicators to compare Mersana Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mersana Therapeutics competition to find correlations between indicators driving Mersana Therapeutics's intrinsic value. More Info.Mersana Therapeutics is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, Mersana Therapeutics' Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Mersana Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Mersana Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mersana Therapeutics' earnings, one of the primary drivers of an investment's value.Mersana Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mersana Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mersana Therapeutics could also be used in its relative valuation, which is a method of valuing Mersana Therapeutics by comparing valuation metrics of similar companies.Mersana Therapeutics is currently under evaluation in return on asset category among related companies.
Mersana Fundamentals
| Return On Equity | -2.66 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (1.96) % | ||||
| Current Valuation | 214.13 M | ||||
| Shares Outstanding | 121.3 M | ||||
| Shares Owned By Insiders | 1.32 % | ||||
| Shares Owned By Institutions | 95.21 % | ||||
| Number Of Shares Shorted | 10.13 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 12.49 X | ||||
| Price To Sales | 12.54 X | ||||
| Revenue | 36.85 M | ||||
| Gross Profit | (146.8 M) | ||||
| EBITDA | (169.44 M) | ||||
| Net Income | (171.67 M) | ||||
| Cash And Equivalents | 225.13 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 33.83 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.32 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (168.88 M) | ||||
| Short Ratio | 3.43 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Target Price | 6.71 | ||||
| Number Of Employees | 123 | ||||
| Beta | 1.51 | ||||
| Market Capitalization | 371.19 M | ||||
| Total Asset | 226.06 M | ||||
| Retained Earnings | (826.36 M) | ||||
| Working Capital | 150.42 M | ||||
| Current Asset | 71.4 M | ||||
| Current Liabilities | 51.32 M | ||||
| Net Asset | 226.06 M |
About Mersana Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mersana Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mersana Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mersana Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 28.1 M | 20.7 M | |
| Total Revenue | 36.9 M | 20.8 M | |
| Cost Of Revenue | 1.5 M | 1.4 M | |
| Stock Based Compensation To Revenue | 0.57 | 0.54 | |
| Sales General And Administrative To Revenue | 1.62 | 1.53 | |
| Research And Ddevelopement To Revenue | 4.02 | 3.82 | |
| Capex To Revenue | (0.06) | (0.06) | |
| Revenue Per Share | 0.32 | 0.30 | |
| Ebit Per Revenue | (4.64) | (4.87) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Mersana Therapeutics Piotroski F Score and Mersana Therapeutics Altman Z Score analysis. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Mersana Stock analysis
When running Mersana Therapeutics' price analysis, check to measure Mersana Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mersana Therapeutics is operating at the current time. Most of Mersana Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mersana Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mersana Therapeutics' price. Additionally, you may evaluate how the addition of Mersana Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Mersana Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.317 | Quarterly Revenue Growth (0.27) | Return On Assets (0.38) | Return On Equity (2.66) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.